Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
191.37
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
59
60
Next >
These S&P500 stocks are moving in today's session
↗
February 12, 2025
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session.
Via
Chartmill
Biogen (BIIB) Q4 2024 Earnings Call Transcript
↗
February 12, 2025
BIIB earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?
↗
February 12, 2025
A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New...
Via
Benzinga
Topics
Economy
Earnings Scheduled For February 12, 2025
↗
February 12, 2025
Via
Benzinga
Breaking Down Biogen: 18 Analysts Share Their Views
↗
January 28, 2025
Via
Benzinga
Wednesday's session: gap up and gap down stock in the S&P500 index
↗
February 12, 2025
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the S&P500 gap up and gap down stocks in today's session.
Via
Chartmill
Biogen Stock Slides To Fresh 12-Year Lows As Profit Outlook Misses, But Retail Snaps Up The Dip
↗
February 12, 2025
The company's breakthrough Alzheimer's drug, Leqembi, generated $87 million in Q4 sales, well ahead of the $67 million analysts expected.
Via
Stocktwits
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
↗
February 12, 2025
Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&D funding from Royalty Pharma.
Via
Benzinga
Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates
February 12, 2025
Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 2.9% year on year to $2.45 billion. Its non-GAAP profit of $3.44 per share was 2.3%...
Via
StockStory
Topics
Artificial Intelligence
Why Investors Might Hammer Biogen Despite Its Earnings Beat
↗
February 12, 2025
Biogen beat Q4 views Wednesday, but guided lower on 2025 profit.
Via
Investor's Business Daily
US Stocks Set For A Cautious Start Ahead Of Inflation Data: Expert Says 'Strong Bull Markets Tend To Roar Back To Life After Corrections'
↗
February 12, 2025
U.S. stock futures fell on Wednesday after a mixed close on Tuesday as Federal Reserve Chairman Jerome Powell Congress testimony.
Via
Benzinga
Topics
Economy
Biogen Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
↗
February 12, 2025
Via
Benzinga
What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?
↗
February 11, 2025
Biogen faces revenue challenges as Leqembi sales lag projections. Investors watch its pipeline expansion and strategic moves amid upcoming Q4 earnings.
Via
Benzinga
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect
February 11, 2025
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for.
Via
StockStory
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
↗
January 31, 2025
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on TikTok.
Via
Benzinga
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
January 31, 2025
From
Biogen Inc.
Via
GlobeNewswire
Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail
↗
January 27, 2025
The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.
Via
Stocktwits
10 Worst Performing Large-Caps Last 12 Months
↗
January 27, 2025
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.
Via
Talk Markets
Topics
Stocks / Equities
FDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
January 26, 2025
From
Biogen Inc.
Via
GlobeNewswire
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
January 23, 2025
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA
From
Biogen Inc.
Via
GlobeNewswire
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
↗
January 17, 2025
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.
Via
Benzinga
Topics
Government
10 Health Care Stocks With Whale Alerts In Today's Session
↗
January 14, 2025
Via
Benzinga
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
↗
January 14, 2025
FDA reviews Eisai and Biogen's BLA for Leqembi SC-AI, targeting Alzheimer's treatment with home-based weekly autoinjector dosing.
Via
Benzinga
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
January 13, 2025
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option
From
Biogen Inc.
Via
GlobeNewswire
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In
↗
January 13, 2025
The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.
Via
Stocktwits
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts
↗
January 13, 2025
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.
Via
Benzinga
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
↗
January 13, 2025
Via
Benzinga
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
↗
January 13, 2025
Via
Benzinga
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
↗
January 13, 2025
Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression.
Via
Benzinga
Enduring Truths for Investors Both New and Seasoned
↗
January 11, 2025
Via
The Motley Fool
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
59
60
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
